Malignancy marker for therapy planning
- Summary
- Blood based test for an early classification of aggressive prostate cancers for personalized therapy planning.
- Technology Benefits
- Early classification of aggressive prostate cancers for personalized therapy planning.
Applicable for analyzing tissue samples and liquid biopsies.
Also relevant for other tumor entities (e.g. esophagus, breast cancer).
Additional biomarker that can be measured in an easy and objective way.
- Technology Application
- Prostate cancer diagnosis and classification, Therapeutic strategies
- Detailed Technology Description
- Vimentin 3 (Vim3) has been discovered as
biomarker, which correlates with the risk of
progression of prostate cancer. Results
show high expression of Vim3 in cells of
metastatic prostate and low expression in
non-metastatic cancer, thus demonstrating
the potential of Vim3 for risk stratification of
localized prostate carcioma to enable personalized therapy planning
- Type of Cooperation
- Licensing
- Application Date
- 02/10/2018 00:00:00
- Application No.
- WO2018EP58923 20180406
- Classes
- - international:
G01N33/50
- cooperative:
G01N33/5091; G01N2800/367
- Others
- Patent application
- ID No.
- 5158
- Country/Region
- Germany
For more information, please click Here
